+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update



Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update



Cancer BioTherapy and Radiopharmaceuticals 13(5): 363-368



Liposome-encapsulated muramyl tripeptide-phosphatidyl ethanolamine (L-MTP-PE) was used in a pilot study for resectable melanoma patients who were at high risk for relapse. We entered 18 evaluable patients. The patient group included: (a) patients with stage III disease and clinically measurable regional metastases at presentation as confirmed by needle biopsy and (b) patients with stage IV disease presenting with measurable and resectable distant metastases confirmed by needle biopsy and limited to lungs, lymph nodes and subcutaneous tissues. L-MTP-PE was given for 4 weeks prior to surgical resection and for an additional 20 weeks postoperatively. Disease-free intervals were then determined based on the date of surgery. A preliminary report published in 1993 indicated an average disease-free interval of 18 months (range 8-33 months). This article presents an updated report on the long-term, disease-free survival status of these patients and shows that of the 18 evaluable patients, 4 remain free of disease for more than 5 years after surgical resection and therapy. The period of survival for these patients ranged from 69 months to more than 91 months (average 80.5 months). Although this was only a pilot study, we believe that the duration of survival indicates that L-MTP-PE may produce significant biologic activity in patients with melanoma, resulting in long-term benefits in terms of tumor eradication.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046554768

Download citation: RISBibTeXText

PMID: 10851426

DOI: 10.1089/cbr.1998.13.363


Related references

Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer BioTherapy 8(4): 307-318, 1993

Cytokine Production and Immune Cell Activation in Melanoma Patients Treated with Liposomal Muramyl Tripeptide (Cgp 19835A Lipid) 1. Cancer Biotherapy 8(4): 307-318, 1993

Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunology ImmunoTherapy 34(4): 211-220, 1992

Phase i study of liposomal cgp 19835a mtp pe muramyl tripeptide derivative. Investigational New Drugs 7(4): 416, 1989

Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. American Journal of Clinical Oncology 18(2): 93-99, 1995

Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. Journal of Drug Targeting 2(5): 391-396, 1994

Phase ii trial of a liposome encapsulated synthetic muramyl tripeptide cgp 19835a in metastatic melanoma. Journal of Cancer Research and Clinical Oncology 116(Suppl. Part 1): 603, 1990

Pilot study of liposomal muramyl tripeptide in melanoma patients cytokine production and activation of monocytes and lymphocytes. Proceedings of the American Association for Cancer Research Annual Meeting 33: 331, 1992

A randomized trial of liposomal muramyl tripeptide for canine melanoma. Proceedings of the American Association for Cancer Research Annual Meeting 36: 493, 1995

Phase iia study of a liposomal muramyl tripeptide in cancer patients initial pronounced immunomodulatory effects in monocytes decrease during prolonged therapy. Pathobiology 60(Suppl. 1): 20, 1992

Evaluation of monocyte functional activity and phenotypic expression following in vivo administration of muramyl tripeptide in liposomes cgp 19835a. Proceedings of the American Association for Cancer Research Annual Meeting 31: 246, 1990

Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs. In Vivo 7(6a): 487-491, 1993

Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Journal of Clinical Oncology 7(12): 1915-1925, 1989

Phase i study of liposomal muramyl tripeptide phosphatidylethanolamine mtp pe in cancer patients. Investigational New Drugs 7(4): 417, 1989

Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?. Cancer Immunology Immunotherapy 36(1): 45-51, 1993